Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSD202 for chronic widespread musculoskeletal nociplastic pain associated with idiopathic mast cell activation syndrome
ACTRN12625000665437Phase 3Withdrawn
- Sponsor
- Quantum BioPharma Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Mast Cell Activation Syndrome (MCAS) and nociplastic pain comparing FSD202 with Placebo (2 arms). Primary endpoint: 30% change in average daily pain intensity score. Planned start Aug 2025; status: withdrawn.
02
Drugs
FSD-PEA
03
Conditions
Mast Cell Activation Syndrome (MCAS)nociplastic pain
Beyond the preview
Go deeper on ACTRN12625000665437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000665437.